ICM
HAE icon

Invenomic Capital Management’s Haemonetics HAE Stock Holding History

Invenomic Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Sell
216,217
-448,512
-67% -$28.8M 0.97% 36
2026
Q1 		$37.5M Buy
+664,729
New +$43.3M 1.72% 15
2025
Q4 		– Sell
-498,317
Closed -$24.3M – 158
2025
Q3 		$24.3M Buy
498,317
+470,502
+1,692% +$29.1M 1.18% 23
2025
Q2 		$2.08M Sell
27,815
-78,915
-74% -$5.22M 0.12% 134
2025
Q1 		$6.78M Buy
+106,730
New +$7.26M 0.34% 92

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invenomic Capital Management's HAE Position: Q2 2026 in Review

Invenomic Capital Management reduced its Haemonetics (HAE) stake by 67% in Q2 2026, selling an estimated $28.8M and leaving 216,217 shares worth $16.2M. The position accounts for 0.97% of the portfolio, ranked #36.

Invenomic Capital Management first reported a position in HAE in Q1 2025 and has held it in 5 quarters since. The position peaked at $37.5M in Q1 2026. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Invenomic Capital Management held 216,217 shares of Haemonetics worth $16.2M as of Q2 2026.
  • Invenomic Capital Management sold 448,512 Haemonetics shares in Q2 2026, an estimated $28.8M.
  • Haemonetics made up 0.97% of Invenomic Capital Management's portfolio in Q2 2026, its #36 holding.
  • Invenomic Capital Management first reported a position in Haemonetics in Q1 2025 and has held it in 5 quarters since.
  • Invenomic Capital Management's Haemonetics position peaked at $37.5M in Q1 2026.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.